Accurate biomarkers accelerate diagnosis, refine prognosis and guide therapy in cardiovascular medicine. The Cardiac Biomarkers and their Clinical Applications session examines protein, nucleic acid, metabolite and imaging-derived markers that improve early detection, risk stratification and monitoring. Presentations will cover high-sensitivity cardiac troponins, natriuretic peptides, novel proteomic signatures, microRNA panels, metabolomics and emerging point-of-care assays. The session addresses how biomarkers inform acute care (triage in chest pain and ACS), chronic management (heart failure phenotyping and therapy monitoring) and trial endpoints (surrogate markers and response biomarkers). Speakers will present analytic validation, clinical performance across subgroups, and implementation pathways including lab-to-bedside translation and cost-effectiveness considerations. Workshops provide practical guidance on assay selection, interpretation, thresholds and integration with imaging and clinical risk models. Sessions also explore regulatory perspectives for biomarker qualification and the role of biomarkers in adaptive trial designs—linking scientific advances to the wider Cardiac Biomarkers Conference objectives.